NEULANDLAB Stock Overview
Manufactures and sells active pharmaceutical ingredients (APIs) in India, Europe, the United States, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 5/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Neuland Laboratories Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹13,802.40 |
| 52 Week High | ₹18,100.00 |
| 52 Week Low | ₹5,021.10 |
| Beta | 1.05 |
| 1 Month Change | -7.40% |
| 3 Month Change | 6.11% |
| 1 Year Change | 169.82% |
| 3 Year Change | 798.48% |
| 5 Year Change | 3,166.84% |
| Change since IPO | 14,428.84% |
Recent News & Updates
Investors Appear Satisfied With Neuland Laboratories Limited's (NSE:NEULANDLAB) Prospects As Shares Rocket 28%
Dec 08
These 4 Measures Indicate That Neuland Laboratories (NSE:NEULANDLAB) Is Using Debt Reasonably Well
Dec 05Concerns Surrounding Neuland Laboratories' (NSE:NEULANDLAB) Performance
Nov 14Neuland Laboratories Limited Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected
Nov 09Here's Why We Think Neuland Laboratories (NSE:NEULANDLAB) Is Well Worth Watching
Nov 08Recent updates
Investors Appear Satisfied With Neuland Laboratories Limited's (NSE:NEULANDLAB) Prospects As Shares Rocket 28%
Dec 08These 4 Measures Indicate That Neuland Laboratories (NSE:NEULANDLAB) Is Using Debt Reasonably Well
Dec 05Concerns Surrounding Neuland Laboratories' (NSE:NEULANDLAB) Performance
Nov 14Neuland Laboratories Limited Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected
Nov 09Here's Why We Think Neuland Laboratories (NSE:NEULANDLAB) Is Well Worth Watching
Nov 08After Leaping 27% Neuland Laboratories Limited (NSE:NEULANDLAB) Shares Are Not Flying Under The Radar
Oct 17Neuland Laboratories Limited's (NSE:NEULANDLAB) Shares Climb 44% But Its Business Is Yet to Catch Up
Aug 22Is Now The Time To Put Neuland Laboratories (NSE:NEULANDLAB) On Your Watchlist?
Aug 02Neuland Laboratories' (NSE:NEULANDLAB) Dividend Will Be Increased To ₹14.00
Jul 12Optimistic Investors Push Neuland Laboratories Limited (NSE:NEULANDLAB) Shares Up 28% But Growth Is Lacking
Jul 02Neuland Laboratories' (NSE:NEULANDLAB) Upcoming Dividend Will Be Larger Than Last Year's
Jun 19Is Neuland Laboratories (NSE:NEULANDLAB) Using Too Much Debt?
Jun 12Neuland Laboratories (NSE:NEULANDLAB) Will Pay A Larger Dividend Than Last Year At ₹14.00
May 21There's Reason For Concern Over Neuland Laboratories Limited's (NSE:NEULANDLAB) Massive 25% Price Jump
Apr 19We Ran A Stock Scan For Earnings Growth And Neuland Laboratories (NSE:NEULANDLAB) Passed With Ease
Apr 15Subdued Growth No Barrier To Neuland Laboratories Limited (NSE:NEULANDLAB) With Shares Advancing 29%
Feb 17Revenue Beat: Neuland Laboratories Limited Exceeded Revenue Forecasts By 8.1% And Analysts Are Updating Their Estimates
Feb 12Neuland Laboratories (NSE:NEULANDLAB) Seems To Use Debt Rather Sparingly
Jan 05The Neuland Laboratories Limited (NSE:NEULANDLAB) Analyst Just Boosted Their Forecasts By A Meaningful Amount
Nov 12Here's Why We Think Neuland Laboratories (NSE:NEULANDLAB) Might Deserve Your Attention Today
Oct 27Neuland Laboratories (NSE:NEULANDLAB) Seems To Use Debt Rather Sparingly
Aug 24Forecast: Analysts Think Neuland Laboratories Limited's (NSE:NEULANDLAB) Business Prospects Have Improved Drastically
Aug 05Neuland Laboratories (NSE:NEULANDLAB) Is Increasing Its Dividend To ₹10.00
Jul 05Neuland Laboratories (NSE:NEULANDLAB) Is Increasing Its Dividend To ₹10.00
Jun 21Neuland Laboratories (NSE:NEULANDLAB) Is Increasing Its Dividend To ₹10.00
May 14Should You Be Adding Neuland Laboratories (NSE:NEULANDLAB) To Your Watchlist Today?
May 12Here's Why Neuland Laboratories (NSE:NEULANDLAB) Can Manage Its Debt Responsibly
Aug 30I Built A List Of Growing Companies And Neuland Laboratories (NSE:NEULANDLAB) Made The Cut
Feb 23The Consensus EPS Estimates For Neuland Laboratories Limited (NSE:NEULANDLAB) Just Fell Dramatically
Feb 03Shareholder Returns
| NEULANDLAB | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -6.9% | 0.8% | -4.3% |
| 1Y | 169.8% | 39.7% | 19.1% |
Return vs Industry: NEULANDLAB exceeded the Indian Pharmaceuticals industry which returned 39.7% over the past year.
Return vs Market: NEULANDLAB exceeded the Indian Market which returned 19.1% over the past year.
Price Volatility
| NEULANDLAB volatility | |
|---|---|
| NEULANDLAB Average Weekly Movement | 9.9% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in IN Market | 9.0% |
| 10% least volatile stocks in IN Market | 4.1% |
Stable Share Price: NEULANDLAB's share price has been volatile over the past 3 months compared to the Indian market.
Volatility Over Time: NEULANDLAB's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of Indian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1984 | 1,643 | Davuluri Rao | www.neulandlabs.com |
Neuland Laboratories Limited manufactures and sells active pharmaceutical ingredients (APIs) in India, Europe, the United States, and internationally. It also provides custom manufacturing solutions, as well as peptide synthesis services. Neuland Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
Neuland Laboratories Limited Fundamentals Summary
| NEULANDLAB fundamental statistics | |
|---|---|
| Market cap | ₹177.15b |
| Earnings (TTM) | ₹2.80b |
| Revenue (TTM) | ₹15.28b |
63.3x
P/E Ratio11.6x
P/S RatioIs NEULANDLAB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NEULANDLAB income statement (TTM) | |
|---|---|
| Revenue | ₹15.28b |
| Cost of Revenue | ₹7.31b |
| Gross Profit | ₹7.97b |
| Other Expenses | ₹5.17b |
| Earnings | ₹2.80b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 217.98 |
| Gross Margin | 52.14% |
| Net Profit Margin | 18.30% |
| Debt/Equity Ratio | 6.7% |
How did NEULANDLAB perform over the long term?
See historical performance and comparisonDividends
0.1%
Current Dividend Yield6%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 20:11 |
| End of Day Share Price | 2024/12/23 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Neuland Laboratories Limited is covered by 5 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Srivathsan Ramachandran | Avendus Spark |
| Rohit Bhat | Batlivala & Karani Securities India Pvt. Ltd. |
| Kameswari V. S. Chavali | FirstCall Research |